Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine in Adults With ADHD and Comorbid Anxiety
NCT06973577Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), anxiety disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2025; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)anxiety disorder
Beyond the preview
Go deeper on NCT06973577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973577.